Dendreon Initiates Phase II Trial of Provenge

Dendreon Corporation announced that the Company has initiated a Phase 2 trial of Provenge (sipuleucel-T), Dendreon’s investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled to undergo a radical prostatectomy.
SunHerald.com